Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Freda Smith

Nurse Practitioner, Family Mobile, AL Nurse Practitioner

NPI 1245758762 CMS profile 10416572

5 Mobile Infirmary Cir Ste 410, Mobile, AL 36607

Open in the dashboard

General payments

$14,240

606 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Freda Smith of Mobile, AL is reported in the CMS Open Payments database as having received $14,240 across 606 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,560 104
2024 General $3,220 127
2023 General $3,668 139
2022 General $2,584 116
2021 General $2,207 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Freda Smith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Freda Smith were reported at $2,560. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Freda Smith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,207 $124 $35–$379 $132
2022 $2,584 $141 $44–$430 $149
2023 $3,668 $154 $49–$476 $160
2024 $3,220 $165 $51–$504 $164
2025 $2,560 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,429 145 payments
  2. Amgen Inc. $2,177 103 payments
  3. Janssen Biotech, Inc. $1,687 60 payments
  4. UCB, Inc. $1,243 61 payments
  5. GlaxoSmithKline, LLC. $1,184 43 payments
  6. Lilly USA, LLC $841 37 payments
  7. Novartis Pharmaceuticals Corporation $798 41 payments
  8. Genzyme Corporation $626 17 payments
  9. AstraZeneca Pharmaceuticals LP $589 27 payments
  10. Radius Health, Inc. $312 15 payments
  11. Other $1,354 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,999 600 payments
  2. Education $241 6 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $2,548 113 payments
  2. TREMFYA $1,836 60 payments
  3. BENLYSTA $1,184 43 payments
  4. SKYRIZI $853 27 payments
  5. TALTZ $840 36 payments
  6. Otezla $776 26 payments
  7. Cimzia $732 41 payments
  8. Enbrel $709 32 payments
  9. SAPHNELO $589 27 payments
  10. KEVZARA $571 19 payments
  11. Other $6,064 310 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

3,787

Median for Nurse Practitioner: 389

Drug cost

$1,916,055

Median for Nurse Practitioner: $21,885

Branded share of claims

33.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 94 $802,732
Cimzia (2 Pack) Certolizumab Pegol Brand 28 $237,824
Enbrel Sureclick Etanercept Brand 20 $149,611
Cosentyx Sensoready (2 Pens) Secukinumab Brand 19 $148,937
Tymlos Abaloparatide Brand 40 $102,732
Rinvoq Upadacitinib Brand 14 $90,610
Forteo Teriparatide Brand 22 $90,498
Enbrel Etanercept Brand 11 $80,026
Benlysta Belimumab Brand 14 $63,906
Otezla Apremilast Brand 11 $49,534

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$57,373

Of which drugs: $129

Medicare patients

376

Average age 74

Services billed

2,005

301 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 45%
Ischemic heart disease 36%
Chronic kidney disease 28%
Diabetes 27%
Depression 26%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 1,040 $106

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $459
$459 — —
SKYRIZI
  • AbbVie, Inc. $311
$311 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $260
$260 — —
RINVOQ
  • AbbVie, Inc. $236
$236 14 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $227
$227 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record